Transplantation of Recombinant Vascular Endothelial Growth Factor (VEGF)-Neural Stem Cells Downregulates Transient Receptor Potential Vanilloid 1 (TRPV1) and Improves Motor Outcome in Spinal Cord Injury

Yun Zeng*, Heng Han*, Bing Tang*, Jie Chen*, Dan Mao*, Min Xiong*

* All the authors contributed equally to the study

Background: Spinal cord injury (SCI) causes a rapid loss of motor neurons, leading to weakness and paralysis. Transplantation of neural stem cells is known to restore the neuronal activity but is inefficient due to limited regenerative capability and low rate of survival. There has been an emphasis on the use of growth factors along with neural stem cells (NSCs) to enhance the neuronal recovery. Transplantation of recombinant NSCs with vascular endothelial growth factor (VEGF) might promote neuronal repair. This effect might be attributed to the reduced transient receptor potential vanilloid 1 (TRPV1) expression following transplantation.

Material/Methods: NSCs were cultured from the embryos of Sprague-Dawley rats (E12.5). Four group of rats (n=10, each) were subjected to SCI and allowed to recover for 1 week. Recombinant VEGF-NSCs, normal NSCs and PBS were intrathecally administered to the rats. VEGF and TRPV-1 expression at mRNA and protein level was evaluated. ELISA was performed to determine the release of neurotrophic factors after the transplantation. Motor neurons and axons were counted and the motor behavioral outcome was assessed using the rota-rod test.

Results: VEGF-NSC transgene transplantation resulted in an enhanced neuronal repair and motor behavioral outcome compared to the normal NSCs transplanted group. VEGF-NSCs increased the release of neurotrophic factors and reduced the expression of TRPV1.

Conclusions: Recombinant VEGF-NSCs transplantation following SCI is more efficacious compared to normal NSC transplantation. This might also be related to a reduced pain in the process of recovery due to reduced TRPV1 expression.

MeSH Keywords: Neural Stem Cells • Spinal Cord Injuries • TRPV Cation Channels • Vascular Endothelial Growth Factor A

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/905264
ANIMAL STUDY

Background

Transplantation of neural stem cells (NSCs) is reported to restore neuronal loss in neurological disorders, including spinal cord injury (SCI) [1,2]. Recently, researchers shifted their attention in developing recombinant neural stem cell transplantation methods to overcome the limitation of low survival rate and the restricted regenerative ability of normal NSCs [2–5]. Vascular endothelial growth factor (VEGF) is vital in angiogenesis, neuronal development, and in neuronal regeneration [6]. It is known that administration of VEGF in combination with NSCs promotes vascularization and alleviates neuronal injury rendering neuroprotection [7,8]. It is indispensable to employ an adequate VEGFA isoform, as some of the isoforms may not be neuroprotective. Out of the 6 VEGFA isoforms (121, 145, 165, 183, 189, and 206), there has always been a wider focus on VEGF165 owing to its predominant expression on the cell surface and extracellular matrix [9,10]. Recombinant VEGF165 NSC transplantation in transient cerebral ischemia causes the NSCs to migrate and to produce VEGF at the injured sites, and to enhance vascularization and neuronal morphology. Furthermore, administration of VEGF165 was reported to increase mechanical allodynia in spinal cord-injured rats [11]. However, the VEGF169 isoform is neuroprotective [10] and the administration of this isoform with NSCs in SCI needs to be investigated.

SCI is associated with the activation of pain transmission pathways and generation of nociceptiv signals upregulating the vanilloid receptors. Transient receptor potential vanilloid 1 (TRPV1) receptors occupy the dorsal roots of the spinal cord and play an integral role in pain transmission following SCI [12,13]. Following an injury, upregulation of TRPV1 indicates a pro-inflammatory response, and selective antagonism might help in alleviating the neuropathic pain [14]. However, TRPV1-mediated regulation of body temperature and inhibition of TRPV1 and agonists were increased. This employed the pain at first, and later, with the persistent release of inflammatory mediators, reduced the pain [15–17]. The efficiency of the use of agonists is under investigation, and downregulation of TRPV1 is still considered to block the pain transmission pathways. In the present study, we compared the effect of the transplantation of recombinant VEGF-NSCs and normal NSCs in rats subjected to contusive SCI. Since VEGF is known to have a direct effect on the TRPV1 expression, we also studied the expression of TRPV1 in NSC-transplanted rats.

Material and Methods

Animals

Sprague-Dawley rats (weighing 12–15 g) were obtained from the SLAC Company, Songjiang District, Shanghai, China. They were kept under optimum conditions (12-h light/dark cycle, 22±0.5°C, and humidity of 50±10%). In addition, pregnant Sprague-Dawley rats (E12.5) were obtained to culture neural stem cells from embryos. The research involving animals was performed according to the relevant guidelines and was approved by the local ethics committee.

Isolation and culture of NSCs

Embryos (E12.5) from pregnant Sprague-Dawley rats were removed under sterile conditions after anaesthetizing the rats using 3% chloral hydrate. The dissected brain tissue from the embryo was trypsinized and filtered to obtain single-cell suspensions. The neural stem cells were washed with PBS and cultured in DMEM/F-12 (Gibco™, ThermoFisher Scientific, Pudong Xinqu, Shanghai Shi, China) medium containing basic fibroblast growth factor (20 ng/ml), epidermal growth factor (20 ng/ml), B27 (20 μl/ml), and insulin (100 ng/ml) (Sigma-Aldrich, Huangpu, Shanghai, China). The cells were cultured for 14 days.

Cloning VEGF into a lentiviral vector and NSC transfection

The target gene VEGF165 fragments were synthesized using PCR and introduced into pGC-FU lentiviral vector to generate a VEGF recombinant lentiviral vector pGC-FU-VEGF165. The efficiency of cloning was confirmed by reverse-transcription PCR and sequencing analysis. For the transfection, pGC-FU-VEGF165 at the multiplicity infection of 50 was incubated with the cultured NSCs for 8 h, after which the culture medium was changed and the transfection was continued for 48 h. The transfection-positive cells were determined using 400 μg/ml of G418 (Sigma-Aldrich, Huangpu, Shanghai, China) for 14 days, and the transplanted cells were further expanded for 2 weeks.

Surgical procedures

Sprague-Dawley rats (weighing 12–15 g) were obtained from the SLAC Company, Songjiang District, Shanghai, China, and divided into 4 groups (n=10, each group). The first group served as the sham-operated control group (SC), the second was the PBS induced group (PBS), the third was the normal NSC-transplanted group (NSC), and the fourth served as the VEGF-NSC transgene transplanted group (VNSC). For the intrathecal administration of transfected NSCs, catheters were placed 1 week prior to inducing SCI in rats. The procedure was carried out in rats under anesthesia, in which a sterile intrathecal catheter (10 cm, 10 μl) was introduced through an opening in the atlantooccipital membrane to the rostral edge of the lumbar region. The catheter was then flushed with 20 μl of saline to ensure flow through the tip. Following this, the catheter was fixed and the opening was sutured. We then injected 10 μl of 2% lidocaine (Sigma-Aldrich, Huangpu, Shanghai, China) to paralyze the hind limbs, and the exact catheter location was
confirmed. The rats were allowed to recover for 1 week. After 7 days, rats were subjected to SCI according to a previously described method. Rats were anesthetized (2.5% isoflurane) (Sigma-Aldrich, Shanghai, China) and placed in a stereotactic frame. The skin was incised and muscle layers in the spinal T9 level were dissected. Th7, Th8, and Th9 were secured using forceps and clamps to perform T8 vertebra laminectomy. Uniform pressure was applied on the spinal cord column tissue using a concave rectangular plate (2.2×5.0 mm) for 5 min [18]. NSC suspensions (normal or transgene NSCs) (2 µl) or buffer were delivered through an infusion pump connected to the catheter. The rats were rehydrated with saline and given Baytril to prevent urinary tract infection. These rats were closely monitored for health status and behavioral changes until 21 days.

**mRNA level expression post-transplantation using RT-qPCR**

mRNA level of VEGF was evaluated at 7 after days of transplantation and mRNA level of TRPV1 was evaluated 21 days following transplantation. Total RNA was obtained using Trizol reagent and the RNA purity was checked using the Nanodrop1000 system (ThermoFisher Scientific, Shanghai, China). The SuperScript VILO cDNA Synthesis Kit (ThermoFisher Scientific, Pudong Xinqu, Shanghai Shi, China) was used for mRNA expression analysis. qPCR was performed on Applied Biosystems™ (ThermoFisher Scientific, Pudong Xinqu, Shanghai Shi, China) using SYBR green qPCR supermix (ThermoFisher Scientific, Pudong Xinqu, Shanghai Shi, China). Specific primers for VEGF and TRPV1 were obtained with GAPDH as the endogenous control to perform normalization of mean Ct values using the 2-ΔΔCt method.

VEGF: Forward: 5’-ATG CAG ACC AAA GAA AGA TAG AG-3’
Reverse: 5’-GCA AGG CCCCA GGG AGC-3’
TRPV1: Forward: 5’-CCT GTG AAT GAG CAT GAT C-3’
Reverse: 5’-TTC CTG CAG AAG AGC C-3’
GAPDH: Forward: 5’-ATG TGT CCG TCG TGG ATC TGA-3’
Reverse: 5’- GCT GTT GAA GTC GCA GGA GAC A-3’

**Immunohistochemistry analysis**

Spinal cord samples from the epicenter of the injury were fixed in 4% paraformaldehyde (Sigma-Aldrich, Shanghai, China) and were prepared for histological processing (n=3, for each group). Tissue samples were embedded in paraffin, paraffin sections (5 μm) were cut, and slices were analyzed in 4% paraformaldehyde (Sigma-Aldrich, Shanghai, China) were incubated with the same primary antibody and secondary antibody (goat anti-VEGF and CD34 monoclonal antibody (1: 100, 1: 50; Abcam, Pudong New District, Shanghai, China) were incubated overnight at 4°C, then incubated with Rhodamine Red (TM)-X goat anti-rabbit IgG (1: 100, Abcam, Pudong New District, Shanghai, China) and FITC goat anti-mouse IgG (1: 100, Abcam, Pudong New District, Shanghai, China). Negative controls were incubated with 0.01 M PBS, instead of primary antibody. The VEGF and TRPV1 staining were visualized under a light microscope (Olympus, Shinjuku-ku Tokyo, Japan) and a fluorescence microscope (Leica Microsystems, Shanghai, China), respectively. Quantification was done using Image-Pro plus v 6.0 software (Media Cybernetics Inc., Rockville, MD, USA). The quantification was done by taking 10 photo-micrographs and the number of positive VEGF stained cells was measured.

**Histological examination of neurons**

Twenty-one days after the surgery, spinal cord sections (5 μm) were cut, paraffin-embedded, and Nissl stained (Sigma-Aldrich, Shanghai, China) to count the number of neurons. Neuronal cell nuclei were positively stained and the numbers were counted using Image J open source application. The quantification was performed by counting the number of positively stained neurons (with intact cell body) in each group and expressed as percentages relative to the total number of cells in the examined tissue section.

**Enzyme-linked immunosorbent assay to detect the release of neurotrophic factors and cytokines**

Sandwich Enzyme Immunoassay kits (R&D systems, Bio-techne, Changning Road Shanghai, China) were used to evaluate the release of neurotrophic factors BDNF, GDNF, and NT-3 in normal and recombinant neural stem cells.

**Western blot analyses**

Protein (20μg) was separated by SDS-PAGE (10%). The blot was blocked using 5% blocking solution (non-fat dry milk in PBS) and then incubated with primary antibodies (Goat anti-VEGF and goat anti-TRPV1, and mouse anti-β actin) (1: 100, Abcam, Pudong New District, Shanghai, China). The blots were then washed 3 times with PBS/0.1% tween followed by the incubation of blots in the labeled secondary antibodies donkey anti-goat IgG and goat anti-mouse. The blots were washed and the proteins were detected using a chemiluminescence system. The Odyssey system (Li-cor Biosciences, St. Lincoln, NE, USA) was used to detect signals and densitometric analysis was performed.
Assessment of motor function and survival

Rats that underwent transplantations were monitored daily to identify the motor behavioral outcomes. The performance was evaluated by an accelerating rota-rod device (4–40 rpm rota-rod) and the length of time the rat remained on the rod was recorded. The investigators who performed this assessment were blind to the experimental details of the treatment.

Statistical analysis

All statistical analyses were performed with GraphPad Prism 7.0. Values are expressed as the mean±SEM, and one-way ANOVA or Student’s t-test was used for statistical analyses. Bonferroni test post-ANOVA was used to compare groups. The experiments were performed in triplicate. The statistical significance was set at p<0.05.

Results

VEGF expression in rats transplanted with VEGF-NSC transgene following SCI

VEGF mRNA expression levels were determined using qRT-PCR and were found to be significantly higher in VEGF-NSC-transplanted rats when compared to other groups (Figure 1A). The results were corroborated via Western blot analyses, with a greater VEGF protein level in VEGF-NSC-transplanted rats (Figure 1B, 1C). NSC-transplanted rats produced a significant increase in VEGF mRNA compared to PBS-treated and sham-operated rats (control), while the increase in VEGF protein level was not significant. VEGF is endogenously upregulated following SCI and the expression was evidently upregulated in the VNSC transplanted experimental group. Immunohistochemical analyses also supported the results showing the rats transplanted
with VNSCs produced more VEGF compared to NSC-transplanted rats (Figure 1D). VEGF-positive staining was quantified in all groups (Figure 1E).

Increase in the motor neurons following VNSC transgene transplantation

To determine the effect of VEGF-NSC transgene transplantation on the loss of motor neurons, the number of motor neurons was counted in the spinal cord sections. Rats transplanted with VNSC had 45% greater density of motor neurons compared to NSC-transplanted rats (Figure 2). These results strongly support that VEGF-induced NSCs restore the loss of neurons following SCI.

VNSC transplantation is also directly related to the increased release of BDNF, GDNF, and NT-3

ELISA evaluated the release of growth factors following VEGF-NSC transgene transplantation and compared it with the normal NSC transplantation. The release of these factors was significantly increased in NSC-VEGF transplanted rats compared to normal NSC
transplantation following SCI (Figure 3A–3C). The stimulated release of these neurotrophic factors and neurite outgrowth-promoting factor positively enhanced the neuronal repair. This adds to the evidence that VEGF recombinant NSC transplantation is a better approach than the transplantation of normal NSCs alone.

VEGF-NSC transgene transplantation induces inhibition of TRPV-1

TRPV-1 expression levels were evaluated 21 days post-transplantation. There was a significant decline in TRPV-1 mRNA expression starting at 7 days post-transplantation (Figure 4A). The protein level of TRPV-1 was also reduced and VNSC transplanted rats exhibited a greater decrease in TRPV-1 mRNA as well as protein compared to the normal NSC-transplanted group (Figure 4B, 4C). This observation shows that there could be an exacerbation of pain in rats transplanted with VNSCs. Immunostaining showed the localization of TRPV-1 with NeuN, a neuronal marker, with decreased TRPV1 expression in the VNSC-induced group of animals (Figure 4D).

Figure 4. Influence of VNSC transplantation on TRPV1 expression. (A) mRNA expression of TRPV-1 was significantly reduced in the VNSC transplanted animal group compared to the NSC-transplanted and PBS transplanted groups. (B) TRPV-1 protein levels also demonstrated a significant decline in VNSC transplanted animals subjected to spinal cord injury. (C) Quantification of TRPV-1 protein expression. (D) Immunostaining showed that there was less TRPV1 expression in VNSC transplanted animals. Red staining represents TRPV1 and Green represents NeuN, a neuronal marker (n=10 spinal cord sections from 3 rats, Scale bar=50 µm). Values are represented as mean ±SEM, * p<0.05 compared to PBS transplanted group, # p<0.05 compared to normal NSC-transplanted group.
There are multifaceted strategies to employ NSCs to counteract the neuronal loss following a brain injury. Cell-based therapy is one of the most promising approaches to neuronal recovery. Protection, and transfection of VEGF plasmids promotes motor survival. Exogenous administration of VEGF renders neuroangiogenesis necessary to impart neuroprotection and survival. Reduced transfection exacerbates neuronal damage. Reduced transfection following SCI has been controversial; a few reports suggested that the introduction of VEGF reduces apoptosis and lesion volume. Furthermore, it was previously shown that blocking TRPV1 would reduce pain. The only roadblock in inhibiting TRPV1 is the risk of developing hypothermia, since it regulates the body temperature as well. However, a very recent study discussed the inhibition of TRPV1 to reduce inflammation and the subsequent pain via a naturally occurring antagonist, omega-9 fatty acid, which still shows that blocking TRPV1 receptor reduces pain.

Our study demonstrates that TRPV1 expression was down-regulated with the VEGF-NSC transplantation following SCI (Figure 4). This reduction in the TRPV1 could also be the result of a direct interaction between VEGF and TRPV1. VEGF regulates TRPV1 expression in a time-dependent manner, where TRPV1 levels were known to be increased during the first, second, and third VEGF instillation and a reduction in TRPV1 following the fourth VEGF instillation in a mouse urinary bladder [29]. At 21 days after VEGF-NSC transplantation, the animals showed a significant improvement in the motor behavioral outcome and this rapid effect might be due to the reduced pain (Figure 5).

**Figure 5.** Rota-rod test to assess the behavioral motor outcome in rats transplanted with VNSCs at 7 and 21 days after spinal cord injury. On the 7th day of assessment, VNSC transplanted groups showed a significant motor response compared to NSC-transplanted animals. Although assessment on the 21st day showed improved motor response in normal NSC-induced groups, VNSC transplantation produced a prominent motor behavioral response. Values are represented as mean ±SEM. * p<0.05 compared to PBS implanted group; # p<0.05 compared to normal NSC-transplanted group.

**Improved motor behavioral outcome post-transplantation**

The neuromuscular behavioral outcome in spinal cord-injured rats post-transplantation was assessed using the rota-rod test. The animals showed significant improvement 7 days after transplantation in VNSC-induced rats compared to normal NSC-induced animals (#p<0.05). The rats showed a marked improvement when assessed on the 21st day, and this could be attributed to the enhanced neuronal repair stimulated by VNSCs (Figure 5).

**Discussion**

Our study focused on the effect of intrathecal administration of recombinant VEGF165-NSCs following contusive SCI in rats with its effect on TRPV-1 expression. The introduction of VEGF following SCI has been controversial; a few reports suggest that the introduction of VEGF reduces apoptosis and lesion volume following SCI and others indicate that VEGF administration exacerbates neuronal damage [19,20]. Reduced VEGF expression following SCI impairs the neurogenesis and angiogenesis necessary to impart neuroprotection and survival [20]. Exogenous administration of VEGF renders neuroprotection, and transfection of VEGF plasmids promotes motor neuronal recovery [21].

Cell-based therapy is one of the most promising approaches to counteract the neuronal loss following a brain injury or SCI [22]. There are multifaceted strategies to employ NSC transplantation, but the effects have been marred by the low survival efficiency, regeneration, and unchecked proliferation. A recent study showed that transplantation of recombinant VEGF165-NSCs enhanced neuronal repair and behavioral outcome following hypoxia-induced brain damage [23]. However, selecting an appropriate VEGF isoform plays an important role in the efficiency of neuronal repair. The VEGF165 isoform of VEGFA is considered neuroprotective compared to 165 isoform; therefore, we used VEGF165 to produce recombinant NSCs. Transplantation of VEGF165 NSCs following SCI increased the motor neuronal count and promoted recovery (Figure 2). The normal NSC transplantation demonstrated less neuronal regeneration, with a reduced neuronal recovery. Therefore, VEGF-NSCs were found to be significantly efficient in increasing the motor neuronal regeneration in rats subjected to contusive SCI.

Transplantation of recombinant NSCs in injured rats also activates the release of neurotrophic and neurite outgrowth-promoting factors [24]. A significant increase in GDNF, BDNF, and NT-3 levels were observed in the current study, which was more significant in VEGF-NSC-transplanted groups than in normal NSC transplantation (Figure 3). These neurotrophic factors were previously shown to be delivered exogenously to enhance neuroprotection or with the NSC grafts to induce autocrine/paracrine effects increasing the generation of neurons post-injury [25,26].

TRPV1 receptors are known for their activation during acute and chronic pain expressed in the central and peripheral nervous systems. TRPV1 agonist resiniferatoxin (RTX) activates TRPV1 with the subsequent desensitization of TRPV1 due to the release of inflammatory mediators and requires a prolonged stimulation [27]. The use of TRPV1 agonists to alleviate pain is still intriguing due to the greater time required to reduce the pain sensation. The only roadblock in inhibiting TRPV1 is the risk of developing hypothermia, since it regulates the body temperature as well. However, a very recent study discussed the inhibition of TRPV1 to reduce inflammation and the subsequent pain via a naturally occurring antagonist, omega-9 fatty acid, which still shows that blocking TRPV1 receptor reduces pain [28].
ANIMAL STUDY

This warrants a further research on the inter-connected molecular mechanisms, as the TRPV-1 receptor is also crucial in regulating temperature.

Conclusions

Our study shows a potential therapeutic approach by the transplantation of recombinant VEGF-induced NSCs in rats following SCI. VNSC transplantation enhanced VEGF expression and promoted the release of neurotrophic factors. This effect was associated with the downregulation of TRPV-1 and improved motor behavioral outcome in VNSC-transplanted animals.

Conflict of interest

None.

References:

1. Vishwakarma SK, Bardia A, Tiwari SK et al: Current concept in neural regeneration research: NSCs isolation, characterization and transplantation in various neurodegenerative diseases and stroke. A review. J Adv Res, 2014; 5: 277–94
2. Tewarie RSN, Hurtado A, Bartels RH et al: Stem cell–based therapies for spinal cord injury. J Spinal Cord Med, 2009; 32: 105–14
3. Zhu JM, Zhao YY, Chen SD et al: Functional recovery after transplantation of neural stem cells modified by brain-derived neurotrophic factor in rats with cerebral ischemia. J Int Med Res, 2011; 39: 488–98
4. Kim SU: Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain Dev, 2007; 29: 193–201
5. Daadi MM, Davis AS, Arac A et al: Human neural stem cell grafts modify microglial response and enhance axonal sprouting in neonatal hypoxic-ischemic brain injury. Stroke, 2010; 41: 516–23
6. Hobson MI, Green CJ, Terenghi G: VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J Anat, 2000; 197: 591–605
7. Tan J, Zheng X, Zhang S et al: Response of the sensorimotor cortex of cerebral palsy rats receiving transplantation of vascular endothelial growth factor 165-transfected neural stem cells. Neural Regen Res, 2014; 9: 1763–69
8. Hwang DH, Lee HJ, Park IH et al: Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther, 2009; 16: 1234–44
9. Robinson CL, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci, 2001; 114: 853–65
10. Herrera JJ, Nesic O, Narayana PA: Reduced vascular endothelial growth factor expression in contusive spinal cord injury. J Neurotrauma, 2009; 26: 995–1003
11. Nesic O, Sundberg LM, Herrera JJ et al: Vascular endothelial growth factor and spinal cord injury pain. J Neurotrauma, 2010; 27: 1793–803
12. Doly S, Fischer J, Salio C, Conath M: The vanilloid receptor-1 is expressed in rat spinal dorsal horn astrocytes. Neurosci Lett, 2004; 357: 123–26
13. Dombourian MG, Turner NA, Gerovac TA et al: B1 and TRPV-1 receptor genes and their relationship to hyperalgesia following spinal cord injury. Spine, 2006; 31: 2778–82
14. Kanal V, Nakazato E, Fujuchi A et al: Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology, 2005; 49: 977–84
15. Ihaferi MD, Elmes SJ, Kendall DA, Chapman V: Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats. Eur J Neurosci, 2005; 22: 361–70
16. Gavva NR, Bannon AW, Surapaneni S et al: The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci, 2007; 27: 3366–74
17. Knottova H, Pappagallo M, Szallasi A: Capsaicin (TRPV1 agonist) therapy for pain relief: Farewell or revival? Clin J Pain, 2008; 24: 142–54
18. Krishna V, Andrews H, Jin X et al: A contusion model of severe spinal cord injury in rats. J Vis Exp, 2013; 78: 50111
19. Widenfalk J, Lipson A, Jabran M et al: Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience, 2003; 120: 951–60
20. Benton RL, Whittemore SR: VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem Res, 2003; 28: 1693–703
21. Tahwar T, Srivastava MVP: Role of vascular endothelial growth factor and other growth factors in post-stroke recovery. Ann Indian Acad Neurol, 2014; 17: 1–6
22. Gu M, Gao Z, Li X et al: Feasibility of diffusion tensor imaging for assessing functional recovery in rats with olfactory ensheathing cell transplantation after contusive spinal cord injury (SCI). Med Sci Monit, 2018; 24: 2961–71
23. Yao Y, Zheng X, Zhang S et al: Transplantation of vascular endothelial growth factor-modified neural stem/progenitor cells promotes the recovery of neurological function following hypoxic-ischemic brain damage. Neural Regen Res, 2016; 11: 1456–63
24. Cai I, Hua F, Yuan L et al: Potential Therapeutic effects of neurotrophins for acute and chronic neurological diseases. Biomed Res Int, 2014; 2014: 601084
25. Sun D: The potential of neural transplantation for brain repair and regeneration following traumatic brain injury. Neural Regen Res, 2016; 11: 18–22
26. Vishwakarma SK, Bardia A, Tiwari SK et al: Current concept in neural regeneration research: NSCs isolation, characterization and transplantation in various neurodegenerative diseases and stroke: A review. J Adv Res, 2014; 5: 277–94
27. Karai L, Brown DC, Mannes AJ et al: Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J Clin Invest, 2004; 113: 1344–52
28. Morales-Lázaro SL, Llorente I, Sierra-Ramírez F et al: Inhibition of TRPV1 channels by a naturally occurring omega-9 fatty acid reduces pain and itch. Nat Commun, 2016; 7: 13092
29. Malykhina AP, Lei Q, Erickson CS et al: VEGF induces sensory and motor peripheral plasticity, alters bladder function, and promotes visceral sensitivity. BMC Physiol, 2012; 12: 15